HISTORY

Pharmena S.A. has commenced collaboration with Amazon EU for the sale of dietary supplements from the Company's portfolio on Amazon e-commerce platforms in Europe and plans to initiate sales in the second quarter of 2024.

Obtaining a patent in Europe for the use of 1-MNA to prevent and reduce the risk of cardiovascular events associated with elevated CRP levels.

The company signed a distribution agreement with Longevity Lunch Lab. LLC for the sale of dietary supplements containing the molecule 1-MNA under the Endotelio brand in the markets of the United States, Canada, and Mexico.

The Company finishes preclinical studies aimed at determining the effective dose of 1-MNA, a drug candidate in pulmonary fibrosis and viral infections.

The company is filing a patent application for the use of 1-MNA in the indication of viral infections and allergic diseases.

Commencement of dermocosmetics sales in China.

PHARMENA, as the first Polish company, successfully registers 1-MNA as novel food in the European Union.

Signing a distribution agreement for dermocosmetics in Egypt, Qatar, and Bahrain.

Signing distribution agreements for dermocosmetics in South Korea, Kuwait, the United Arab Emirates, and Oman.

Obtaining a patent in the USA for the use of 1-MNA in correcting lipid profile disorders.

Obtaining a patent in Canada for the use of 1-MNA in combination with statins in the treatment of lipid profile disorders.

Commencement of cooperation with Lubfarm S.A.

Obtaining a patent in Japan for the oral use of 1-MNA in combination with statins in the treatment of lipid profile disorders.

MARCH-APRIL 2013 Obtaining a patent in Europe and the USA for the oral use of 1-MNA in combination with non-steroidal anti-inflammatory drugs in the treatment of pain and inflammation of various origins.

PHARMENA initiates collaboration with Rossmann and Hebe.

The company expands its product range with additional products in the Dermena, Accos, and Allerco lines, including the sensitive skin care cream introduced to the market in 2005.

PHARMENA establishes Pharmena North America Inc. based in Boston (USA), which will focus on conducting clinical trials in the USA and Canada. In November 2006, PHARMENA establishes DERMENA North America Inc. also based in Boston (USA), with the task of introducing dermocosmetics produced by the company to the American market.

In the Polish market, the company introduces its first original products - DERMENA shampoo preventing excessive hair loss, THERMI soothing and caring gel, and ACCOS anti-acne gel. The introduction of innovative preparations, protected by patents in several countries, is the culmination of many years of research conducted by the Lodz University of Technology in collaboration with the Medical University of Lodz.